AU2003241346A1 - Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer - Google Patents

Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer

Info

Publication number
AU2003241346A1
AU2003241346A1 AU2003241346A AU2003241346A AU2003241346A1 AU 2003241346 A1 AU2003241346 A1 AU 2003241346A1 AU 2003241346 A AU2003241346 A AU 2003241346A AU 2003241346 A AU2003241346 A AU 2003241346A AU 2003241346 A1 AU2003241346 A1 AU 2003241346A1
Authority
AU
Australia
Prior art keywords
pentamidine
methods
same
therapeutic compositions
treat cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003241346A
Other versions
AU2003241346A8 (en
Inventor
Taolin Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/238,007 external-priority patent/US7416723B2/en
Priority claimed from US10/354,357 external-priority patent/US20030161893A1/en
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of AU2003241346A1 publication Critical patent/AU2003241346A1/en
Publication of AU2003241346A8 publication Critical patent/AU2003241346A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003241346A 2002-05-01 2003-05-01 Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer Abandoned AU2003241346A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US37678902P 2002-05-01 2002-05-01
US60/376,789 2002-05-01
US10/238,007 2002-09-09
US10/238,007 US7416723B2 (en) 2001-09-07 2002-09-09 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US10/354,357 US20030161893A1 (en) 2001-09-07 2003-01-30 PTPase inhibitors and methods of using the same
US10/354,357 2003-01-30
US46073503P 2003-04-04 2003-04-04
US60/460,735 2003-04-04
PCT/US2003/013744 WO2003092616A2 (en) 2002-05-01 2003-05-01 Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer

Publications (2)

Publication Number Publication Date
AU2003241346A1 true AU2003241346A1 (en) 2003-11-17
AU2003241346A8 AU2003241346A8 (en) 2003-11-17

Family

ID=29408046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003241346A Abandoned AU2003241346A1 (en) 2002-05-01 2003-05-01 Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer

Country Status (2)

Country Link
AU (1) AU2003241346A1 (en)
WO (1) WO2003092616A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008347A (en) 2007-02-06 2009-10-19 Lixte Biotechnology Holdings I Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
CN102573826A (en) * 2009-05-01 2012-07-11 奥克兹美制药公司 Pentamidine combinations for treating cancer
MX2015007945A (en) * 2012-12-21 2016-02-16 Verlyx Pharma Inc Uses and methods for the treatment of liver diseases or conditions.
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2023144830A1 (en) 2022-01-30 2023-08-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Zika m protein blockers as anti-zika virus agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE77947T1 (en) * 1987-04-09 1992-07-15 Fisons Plc PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE.
US6020179A (en) * 1996-10-03 2000-02-01 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human tyrosine phosphatases
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2003092616A2 (en) 2003-11-13
WO2003092616A3 (en) 2004-07-01
AU2003241346A8 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
AU2003257937A1 (en) Methods and compositions for treatment of dermal conditions
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1663259A4 (en) Compositions and methods for treatment of cancer
AU2003259735A1 (en) Small-mer compositions and methods of use
EP1816996A4 (en) Methods and therapeutic compositions comprising plant extracts for the treatment of cancer
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002311903A1 (en) Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto
AU2003301240A1 (en) Skin cleanser compositions and methods of use
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
AU2002350254A1 (en) Novel carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
AU2002952597A0 (en) Topical parasiticide formulations and methods of treatment
AU2003211009A1 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
AU2003241346A1 (en) Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2002307100A1 (en) Use of tumor necrosis factor inhibitors to treat cardiovascular disease
EP1575497A4 (en) Novel composition and methods for the treatment of psoriasis
AU2003239157A1 (en) Cascade esters of camptothecins and methods of treating cancer using these compounds
AU2003223805A1 (en) Methods of using thiazolidine derivatives to treat cancer or inflammation
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003298708A1 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
IL164218A0 (en) Use of interleukin-19 to treat ovarian cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase